Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 91,437,680
  • Shares Outstanding, K 2,532,900
  • Annual Sales, $ 22,465 M
  • Annual Income, $ 3,001 M
  • 36-Month Beta 0.63
  • Price/Sales 4.11
  • Price/Cash Flow 10.90
  • Price/Book 6.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.63 +0.55%
on 06/19/18
37.30 -3.95%
on 05/22/18
-0.51 (-1.39%)
since 05/18/18
3-Month
34.11 +5.03%
on 03/23/18
37.30 -3.95%
on 05/22/18
+1.26 (+3.63%)
since 03/19/18
52-Week
28.43 +26.01%
on 07/27/17
37.30 -3.95%
on 05/22/18
+1.19 (+3.42%)
since 06/19/17

Most Recent Stories

More News
Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

AGLE : 10.58 (-2.85%)
AZN : 35.80 (-0.83%)
ILMN : 284.27 (-1.59%)
VRX : 24.17 (+2.59%)
Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx

The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.

AZN : 35.80 (-0.83%)
MRK : 60.83 (-0.26%)
MYGN : 39.46 (-1.77%)
PFE : 36.19 (+0.08%)
AstraZeneca to Share Latest Data from an Industry-Leading Portfolio That Aims to Advance Clinical Understanding of Diabetes and CV Risk Management at ADA 2018

--Latest data from the DEPICT clinical program evaluating dapagliflozin to address an unmet need for oral therapy in adult patients with type 1 diabetes

AZN : 35.80 (-0.83%)
Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.

AZN : 35.80 (-0.83%)
MRK : 60.83 (-0.26%)
LLY : 86.32 (+0.24%)
ABBV : 97.36 (-1.14%)
RHHBY : 26.4500 (+0.23%)
GLMD : 15.32 (+2.75%)
GSK : 40.95 (-0.78%)
Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate

Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.

AZN : 35.80 (-0.83%)
JNJ : 122.38 (+0.87%)
MRK : 60.83 (-0.26%)
LLY : 86.32 (+0.24%)
Alzheimer's Research Stumbles Again: What's the Road Ahead?

The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.

AZN : 35.80 (-0.83%)
JNJ : 122.38 (+0.87%)
MRK : 60.83 (-0.26%)
LLY : 86.32 (+0.24%)
NVS : 73.60 (-0.66%)
PFE : 36.19 (+0.08%)
BIIB : 293.06 (+1.36%)
Bladder Cancer: Pipeline Review, H1 2018 - Key Company Analysis, Drug Profiles, and Opportunities - ResearchAndMarkets.com

The "Bladder Cancer - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering. Bladder Cancer - Pipeline Review, H1 2018, provides comprehensive information...

BAYRY : 31.7500 (+1.28%)
JNJ : 122.38 (+0.87%)
MRK : 60.83 (-0.26%)
SRRA : 3.49 (-2.51%)
ALPMF : 15.4700 (-4.33%)
NVS : 73.60 (-0.66%)
ADAP : 11.74 (-5.17%)
AMGN : 185.01 (+0.58%)
CELGZ : 0.28 (-22.22%)
PFE : 36.19 (+0.08%)
BMY : 53.42 (-0.43%)
FSCGF : 5.3000 (unch)
AZN : 35.80 (-0.83%)
AAVXF : 8.0000 (unch)
LLY : 86.32 (+0.24%)
SGEN : 65.04 (-1.08%)
ESALF : 74.5000 (+4.41%)
GSK : 40.95 (-0.78%)
BVNKF : 30.4100 (-7.29%)
MKKGY : 19.1400 (-0.83%)
OPHLF : 25.9100 (+5.67%)
Hepatocellular Carcinoma: 2018 Global Pipeline Review, H1 - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

The "Hepatocellular Carcinoma - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering. This latest pipeline guide provides comprehensive information...

BAYRY : 31.7500 (+1.28%)
NSPXD : 0.5600 (-1.75%)
JNJ : 122.38 (+0.87%)
MRK : 60.83 (-0.26%)
NVS : 73.60 (-0.66%)
ABBV : 97.36 (-1.14%)
INO : 4.32 (-2.48%)
AMGN : 185.01 (+0.58%)
CELGZ : 0.28 (-22.22%)
OMER : 18.63 (-4.12%)
PFE : 36.19 (+0.08%)
BMY : 53.42 (-0.43%)
ONCY : 6.04 (-0.82%)
NYMX : 3.33 (-1.77%)
AZN : 35.80 (-0.83%)
LLY : 86.32 (+0.24%)
TKPYY : 18.9600 (-1.89%)
GILD : 70.60 (+2.23%)
ESALF : 74.5000 (+4.41%)
GSK : 40.95 (-0.78%)
MKKGY : 19.1400 (-0.83%)
OPHLF : 25.9100 (+5.67%)
AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer

AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.

AZN : 35.80 (-0.83%)
MRK : 60.83 (-0.26%)
LLY : 86.32 (+0.24%)
HLUYY : 72.1400 (-1.31%)
New Research: Key Drivers of Growth for Ingersoll-Rand PLC, McEwen Mining, Sociedad Quimica y Minera S.A., AstraZeneca, Worldpay, and Silver Wheaton -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ingersoll-Rand PLC (NYSE:IR),...

MUX : 2.16 (+0.93%)
AZN : 35.80 (-0.83%)
WPM : 22.01 (-0.86%)
IR : 90.95 (-1.16%)
WP : 84.69 (-0.52%)
SQM : 48.19 (-2.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AZN with:

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 36.26
1st Resistance Point 36.18
Last Price 35.80
1st Support Level 36.00
2nd Support Level 35.90

See More

52-Week High 37.30
Last Price 35.80
Fibonacci 61.8% 33.91
Fibonacci 50% 32.86
Fibonacci 38.2% 31.82
52-Week Low 28.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar